Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells

S E Damon1, S R Plymate, J M Carroll

  • 1Geriatric Research Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Tacoma, Washington 98493, USA.

Endocrinology
|January 6, 2001
PubMed

Insights

Prostate cancer progression significantly reduces the type 1 insulin-like growth factor receptor (IGF-IR). Increased WT1 tumor suppressor expression likely represses IGF-IR gene transcription, inhibiting cell proliferation in metastatic prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Prostate cancer progression involves a decrease in type 1 insulin-like growth factor receptor (IGF-IR) expression.
  • The WT1 tumor suppressor is implicated in prostate cancer and regulates IGF-IR gene expression.

Purpose of the Study:

  • To investigate if decreased IGF-IR expression in prostate cancer is transcriptionally regulated.
  • To determine the role of WT1 in repressing IGF-IR gene expression in prostate cancer cells.

Main Methods:

  • Utilized P69 (benign) and M12 (metastatic) prostate cell lines with differing IGF-IR levels.
  • Assessed IGF-IR promoter activity using luciferase reporter assays with various IGF-IR gene constructs.
  • Investigated the effect of WT1 overexpression in P69 cells on endogenous IGF-IR expression and promoter activity.

Main Results:

  • M12 cells exhibited significantly lower IGF-IR promoter activity compared to P69 cells.
  • Overexpression of WT1 in P69 cells led to decreased endogenous IGF-IR expression and reduced promoter activity.
  • Reduced IGF-IR expression inhibited IGF-I-stimulated prostate cancer cell proliferation.

Conclusions:

  • Decreased IGF-IR expression in malignant prostate epithelium is primarily due to transcriptional repression.
  • Increased WT1 tumor suppressor expression in metastatic prostate cancer contributes to IGF-IR gene repression.
  • WT1-mediated repression of IGF-IR impacts prostate cancer cell proliferation.

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...